Other HBV companies (e.g. ABUS) have faced a similar issue and have dealt with it in a way that I didn’t find convincing.
It’s a pretty good bet that IMCR will characterize any observed LFT abnormalities as the “good” kind (the immune system has been re-activated against the virus-laden hepatocytes) rather than the “bad” kind (the drug has liver toxicity).
News 
Market Data 
Discover 
